https://www.selleckchem.com/pr....oducts/4-aminobutyri
The results were compared to the patient's individual in vivo response to therapy. The cytotoxicity assay of PDMs and TILs showed asignificant therapeutic response (p = 0.0004) to therapy with aprogrammed cell death protein1 (PD-1) inhibitor and lenvatinib compared to the control. The in vitro results correlated positively with the in vivo data. In the future, patient-derived models could predict response to cancer therapy and may help to optimize treatment decision-making. The cytotoxicity assay of PDMs and TILs showed a si
Like
Comment
Share
